Max Healthcare Institute Second Quarter 2025 Earnings: Misses Expectations

Simply Wall St

November 07, 2024

Max Healthcare Institute (NSE:MAXHEALTH) Second Quarter 2025 Results

Key Financial Results

Revenue: ₹17.5b (up 28% from 2Q 2024).
Net income: ₹2.82b (up 1.9% from 2Q 2024).
Profit margin: 16% (down from 20% in 2Q 2024). The decrease in margin was driven by higher expenses.
EPS: ₹2.90 (up from ₹2.85 in 2Q 2024).

earnings-and-revenue-growth — NSEI:MAXHEALTH Earnings and Revenue Growth November 7th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Max Healthcare Institute Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 21%.

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in India.

Performance of the Indian Healthcare industry.

The company's shares are up 8.8% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Max Healthcare Institute's balance sheet health.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.